I-Mab at Jefferies London Healthcare Conference TranscriptNov 14, 2023- Half Year 2023 I-Mab Earnings Call TranscriptAug 17, 2023$2.3 (-2.95%)Earnings
- Full Year 2022 I-Mab Earnings Call TranscriptMar 31, 2023$3.46 (-1.70%)Earnings
- I-Mab Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab Call TranscriptSep 12, 2022
- Half Year 2022 I-Mab Earnings Call TranscriptAug 30, 2022$5.98 (+2.57%)Earnings
- I-Mab R&D Day TranscriptJul 20, 2022
- I-Mab TJD5 Phase 2 Clinical Trial Data Update Call TranscriptMay 27, 2022
- Full Year 2021 I-Mab Earnings Call TranscriptMar 29, 2022$19.39 (+15.07%)Earnings
- I-Mab at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- I-Mab Corporate Call TranscriptDec 21, 2021
- I-Mab Most Recent Clinical Data Update Conference Call -- English Session TranscriptDec 14, 2021
- I-Mab and Jumpcan To Announce its Strategic Commercial Partnership on Eftansomatropin Alfa - Special Call TranscriptNov 10, 2021
- Half Year 2021 I-Mab Earnings & Corporate Progress Update Conference Call TranscriptAug 31, 2021
- I-Mab to Discuss Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 Call TranscriptJun 07, 2021
- I-Mab at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- I-Mab Corporate Analyst Meeting TranscriptApr 26, 2021
- Full Year 2020 I-Mab Earnings Call TranscriptMar 29, 2021$44.38 (-4.80%)Earnings
- IMAB Lemzoparlimab Phase 1 Clinical Trial Data Update Conference Call TranscriptNov 13, 2020
- I-Mab SITC Data Conference Call TranscriptNov 09, 2020
- I-Mab Company Update Conference Call TranscriptSep 04, 2020
- Half Year 2020 I-Mab Earnings Call TranscriptAug 31, 2020$39.44 (+27.23%)Earnings
- I-Mab Update Conference Call TranscriptMay 28, 2020
- I-Mab at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Full Year 2019 I-Mab Earnings Call TranscriptMar 31, 2020$13 (+4.00%)Earnings
Half Year 2021 I-Mab Earnings & Corporate Progress Update Conference Call Transcript
Thank you, everyone. Thank you for standing by, and welcome to I-Mab 2021 interim business update and the financial results conference call.
Earlier today, we issued a press release detailing I-Mab's significant pipeline progress and the corporate highlights during the first half of 2021 and upcoming milestones for the rest of 2021 as well as a review of our financial results for the first 6 months in 2021. The press release can be accessed on the investor portion of our website.
Joining me today on the call from I-Mab's senior management team are Dr. Jingwu Zang, our Founder, Chairman and Director; and Dr. Joan Shen, our Chief Executive Officer. Dr. Zang will provide a high-level overview of our recent achievements and the strategy going forward. He will then highlight the progress we have made in our key clinical programs and upcoming milestones and catalysts. Dr. Shen will then comment on the status of other important clinical assets and corporate achievements. I will then provide a brief summary of our financial results and our preparation for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
